Substituted morpholine derivatives and their use as therapeutic agents
    2.
    发明授权
    Substituted morpholine derivatives and their use as therapeutic agents 失效
    取代的吗啉衍生物及其作为治疗剂的用途

    公开(公告)号:US5612337A

    公开(公告)日:1997-03-18

    申请号:US663201

    申请日:1996-06-13

    摘要: The present invention relates to compounds of formula (I), wherein R.sup.1 is hydrogen, halogen, C.sub.1-6 C alkyl, C.sub.1-6 alkoxy, CF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substituted by C.sub.1-4 alkoxy, where R.sup.a and R.sup.b are hydrogen or C.sub.1-4 alkyl; R.sup.2 is hydrogen, halogen, C .sub.1-6 alkyl, C.sub.1-6 alkoxy substituted by C.sub.1-4 alkoxy or CF.sub.3 ; R.sup.3 is hydrogen, halogen or CF.sub.3 ; R.sup.4 is selected from the definitions of R.sup.1 ; R.sup.5 is selected from the definitions of R.sup.2 ; R.sup.6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by .dbd.O, .dbd.S or a C.sub.1-4 alkyl group, and optionally substituted by an aminoalkyl group; R.sup.9a and R.sup.9b are hydrogen or C.sub.1-4 alkyl, or R.sup.9a and R.sup.9b are joined to form a C.sub.5-7 ring; X is C.sub.1-4 alkylene optionally substituted by oxo; and Y is a C.sub.1-4 alkyl group optionally substituted by hydroxyl; with the proviso that if Y is C.sub.1-4 alkyl, R.sup.6 is substituted at least by an aminoalkyl group; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.

    摘要翻译: PCT No.PCT / GB94 / 02819 Sec。 371日期:1996年6月13日 102(e)日期1996年6月13日PCT 1994年12月23日PCT公布。 公开号WO95 / 18124 日期:1995年7月6日(一)本发明涉及式(I)化合物,其中R 1为氢,卤素,C 1-6烷基,C 1-6烷氧基,CF 3,NO 2,CN,SR a,SOR a ,SO 2 R a,CO 2 R a,CONR a R b,C 2-6烯基,C 2-6炔基或被C 1-4烷氧基取代的C 1-4烷基,其中R a和R b是氢或C 1-4烷基; R2是氢,卤素,C 1-6烷基,被C 1-4烷氧基或CF 3取代的C 1-6烷氧基; R3是氢,卤素或CF3; R4选自R1的定义; R5选自R2的定义; R6是含有2或3个氮原子的5元或6元杂环,任选被= O,= S或C 1-4烷基取代,并且任选被氨基烷基取代; R9a和R9b是氢或C1-4烷基,或R9a和R9b连接形成C5-7环; X是任选被氧代取代的C 1-4亚烷基; Y是任选被羟基取代的C 1-4烷基; 条件是如果Y是C 1-4烷基,则R6至少被氨基烷基取代; 及其药学上可接受的盐和前药。 该化合物特别用于治疗疼痛,炎症,偏头痛和呕吐。

    Heterocyclic amide derivatives as tachykinin antagonists
    4.
    发明授权
    Heterocyclic amide derivatives as tachykinin antagonists 失效
    杂环酰胺衍生物作为速激肽拮抗剂

    公开(公告)号:US5612336A

    公开(公告)日:1997-03-18

    申请号:US373195

    申请日:1995-01-13

    摘要: Compounds of formula (I), and salts and prodrugs thereof, wherein Q.sup.1 is phenyl substituted by one or more halo; optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl; the dotted line represents an optional covalent bond; one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y together form a group .dbd.O or .dbd.NOR.sup.5 where R.sup.5 is H or C.sub.1-6 alkyl; R.sup.1 is H or C.sub.1-6 alkyl. R.sup.2 is CO--W--R.sup.6 where W represents a bond or a hydrocarbon chain of 1-6 carbon atoms and R.sup.6 is an azacyclic or azabicyclic group; R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; and R.sup.4 is phenyl optionally substituted by 1-3 of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists useful in therapy.

    摘要翻译: PCT No.PCT / GB93 / 01415 Sec。 371日期1995年1月13日 102(e)日期1995年1月13日PCT提交1993年7月6日PCT公布。 出版物WO94 / 01402 日期:1994年1月20日式(I)化合物及其盐和前药其中Q1是被一个或多个卤素取代的苯基; 任选取代的萘基,吲哚基,苯并噻吩基,苯并呋喃基,苄基或芴基; 虚线表示任选的共价键; X和Y之一是H,另一个是羟基或C 1-6烷氧基,或X和Y一起形成基团= O或= NOR 5,其中R 5是H或C 1-6烷基; R1是H或C1-6烷基。 R2是CO-W-R6,其中W表示1-6个碳原子的键或烃链,R6是氮杂环或氮杂双环基; R3是H,C1-6烷基或C2-6烯基; R4是任选被1-3个C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基甲硅烷基,OR a,SR a,SOR a,NR a R b,NR a COR b,NR a CO 2 R b,CO 2 R a或CONR a R b, 其中R a和R b是H,C 1-6烷基,苯基或三氟甲基; 是用于治疗的速激肽拮抗剂。

    Hetercyclic compounds, processes for their preparation and
pharmaceutical compositions containing them
    5.
    发明授权
    Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them 失效
    异环化合物,其制备方法和含有它们的药物组合物

    公开(公告)号:US5328927A

    公开(公告)日:1994-07-12

    申请号:US021826

    申请日:1993-02-24

    CPC分类号: C07D333/58 C07D209/16

    摘要: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein Q.sup.1 is halo substituted phenyl; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl; . . is an optional covalent bond;one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y are together .dbd.0 or .dbd.NOR.sup.5 ;R.sup.1 and R.sup.2 are H; C.sub.1-6 alkyl optionally substituted by hydroxy, cyano, COR.sup.c, CO.sub.2 R.sup.c, CONR.sup.c R.sup.d, or NR.sup.c R.sup.d (where R.sup.c and R.sup.d are H, C.sub.1-6 alkyl or phenyl(C.sub.0-4 alkyl) optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo and trifluoromethyl); phenyl(C.sub.1-4 alkyl) (optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo or trifluoromethyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; COC.sub.1-6 alkylNR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ;R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; andR.sup.4 is phenyl optionally substituted by C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists.

    摘要翻译: 式(I)化合物及其盐和前药其中Q 1是卤素取代的苯基; 萘基; 吲哚基 苯硫酚 苯并呋喃基 苄基; 或芴基; 。 。 。 是可选的共价键; X和Y之一是H,另一个是羟基或C 1-6烷氧基,或X和Y一起= 0或= NOR5; R1和R2是H; 任选被羟基,氰基,CORc,CO2Rc,CONRcRd或NRcRd取代的C 1-6烷基(其中R c和R d为H,任选被C 1-6烷基,C 1-6烷氧基,卤素和三氟甲基取代的C 1-6烷基或苯基(C 0-4烷基) ); 苯基(C 1-4烷基)(任选被C 1-6烷基,C 1-6烷氧基,卤素或三氟甲基取代); CORC; CO2Rc; CONRcRd; COC 1-6烷基NR c R d; CONRcCOORd; 或SO2Rc; R3是H,C1-6烷基或C2-6烯基; R4是任选被C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基甲硅烷基,OR a,SR a,SOR a,NR a R b,NR a COR b,NR a CO 2 R b,CO 2 R a或CONR a R b任意取代的苯基,其中R a和R b是 H,C 1-6烷基,苯基或三氟甲基; 速激肽拮抗剂。

    Tachykinin antagonists
    6.
    发明授权
    Tachykinin antagonists 失效
    速激肽拮抗剂

    公开(公告)号:US5554627A

    公开(公告)日:1996-09-10

    申请号:US428065

    申请日:1995-04-27

    摘要: Compounds of formula (I), wherein Q.sup.1 represents an aryl group; the dotted line represents an optional covalent bond; one of X and Y represents H and the other represents hydroxy or C.sub.1-6 alkoxy, or X and Y together form a group .dbd.O or .dbd.NOR.sup.5 where R.sup.5 is H or C.sub.1-6 alkyl; Z represents O, S or NR.sup.2, where R.sup.2 is H or C.sub.1-6 alkyl; W represents a bond or a saturated or unsaturated hydrocarbon chain of 1, 2, 3, 4, 5 or 6 carbon atoms; R.sup.1 represents H or C.sub.1-6 alkyl. R.sup.3 represents H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; R.sup.4 represents an optionally substituted phenyl group; and R.sup.6 represents a specified amino group or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group; and salts and prodrugs are tachykinin receptor antagonists.

    摘要翻译: PCT No.PCT / GB93 / 02213 371日期:1995年04月27日 102(e)日期1995年4月27日PCT提交1993年10月27日PCT公布。 公开号WO94 / 10167 (I)其中Q1表示芳基的式(I)化合物; 虚线表示任选的共价键; X和Y之一表示H,另一个表示羟基或C 1-6烷氧基,或X和Y一起形成基团= O或= NOR5,其中R5是H或C1-6烷基; Z表示O,S或NR2,其中R2是H或C1-6烷基; W表示具有1,2,3,4,5或6个碳原子的键或饱和或不饱和烃链; R1表示H或C1-6烷基。 R 3表示H,C 1-6烷基或C 2-6烯基; R4表示任选取代的苯基; 并且R 6表示指定的氨基或任选取代的芳族或非芳族氮杂环或氮杂双环基; 盐和前药是速激肽受体拮抗剂。

    Heterocyclic compounds, processes for their preparation and
pharmaceutical compositions containing them
    7.
    发明授权
    Heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them 失效
    杂环化合物,其制备方法和含有它们的药物组合物

    公开(公告)号:US5514718A

    公开(公告)日:1996-05-07

    申请号:US227943

    申请日:1994-04-15

    CPC分类号: C07D333/58 C07D209/16

    摘要: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein Q.sup.1 is halo substituted phenyl; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl; . . is an optional covalent bond;one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y are together .dbd.O or .dbd.NOR.sup.5 ;R.sup.1 and R.sup.2 are H; C.sub.1-6 alkyl optionally substituted by hydroxy, cyano, COR.sup.c, CO.sub.2 R.sup.c, CONR.sup.c R.sup.d, or NR.sup.c R.sup.d (where R.sup.c and R.sup.d are H, C.sub.1-6 alkyl or phenyl(C.sub.0-4 alkyl) optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo and trifluoromethyl); phenyl(C.sub.1-4 alkyl) (optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo or trifluoromethyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; COC.sub.1-6 alkylNR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ;R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; andR.sup.4 is phenyl optionally substituted by C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists.

    摘要翻译: 式(I)化合物及其盐和前药其中Q 1是卤素取代的苯基; 萘基; 吲哚基 苯硫酚 苯并呋喃基 苄基; 或芴基; 。 。 。 是一个可选的共价键; X和Y之一是H,另一个是羟基或C 1-6烷氧基,或X和Y一起= O或= NOR 5; R1和R2是H; 任选被羟基,氰基,CORc,CO2Rc,CONRcRd或NRcRd取代的C 1-6烷基(其中R c和R d为H,任选被C 1-6烷基,C 1-6烷氧基,卤素和三氟甲基取代的C 1-6烷基或苯基(C 0-4烷基) ); 苯基(C 1-4烷基)(任选被C 1-6烷基,C 1-6烷氧基,卤素或三氟甲基取代); CORC; CO2Rc; CONRcRd; COC 1-6烷基NR c R d; CONRcCOORd; 或SO2Rc; R3是H,C1-6烷基或C2-6烯基; R4是任选被C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基甲硅烷基,OR a,SR a,SOR a,NR a R b,NR a COR b,NR a CO 2 R b,CO 2 R a或CONR a R b任意取代的苯基,其中R a和R b是 H,C 1-6烷基,苯基或三氟甲基; 速激肽拮抗剂。

    Oxazolidindione substituted indole derivatives
    9.
    发明授权
    Oxazolidindione substituted indole derivatives 失效
    恶唑烷二酮取代吲哚衍生物

    公开(公告)号:US5334606A

    公开(公告)日:1994-08-02

    申请号:US982794

    申请日:1992-11-30

    申请人: Angus M. MacLeod

    发明人: Angus M. MacLeod

    摘要: Compounds of formula (I): ##STR1## wherein Q.sup.1 represents a phenyl group substituted by one or more halo; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl;R.sup.1 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl;R.sup.2 is phenyl(C.sub.1-4 alkyl) optionally substituted in the phenyl ring by one or more groups selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, SR.sup.b, SOR.sup.b, SO.sub.2 R.sup.b, OR.sup.b, NR.sup.b R.sup.c, NR.sup.b COR.sup.c, NR.sup.b COOR.sup.c, COOR.sup.b or CONR.sup.b R.sup.c, where R.sup.b and R.sup.c independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; andZ is O, S, NR.sup.8 or CR.sup.9 R.sup.10, where R.sup.8 represents H C.sub.1-6 alkyl, phenyl, phenyl(C.sub.1-4 alkyl), COR.sup.11, COOR.sup.11, CONR.sup.9 R.sup.10 where R.sup.11 is phenyl, phenyl(C.sub.1-4 alkyl) or C.sub.1-6 alkyl, and R.sup.9 and R.sup.10 are each H, C.sub.1-6 alkyl, phenyl or phenyl(C.sub.1-4 alkyl); are tachykinin antagonists. They and their compositions are useful in medicine.

    摘要翻译: 式(I)的化合物:其中Q1表示被一个或多个卤素取代的苯基; 萘基; 吲哚基 苯硫酚 苯并呋喃基 苄基; 或芴基; R1是H,C1-6烷基或C2-6烯基; R2是在苯环中被选自C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,SR b,SOR b,SO 2 R b,OR b,NR b R c中的一个或多个基团任意取代的苯基(C 1-4烷基) NRbCORc,NRbCOORc,COORb或CONRbRc,其中Rb和Rc独立地表示H,C1-6烷基,苯基或三氟甲基; 并且Z是O,S,NR8或CR9R10,其中R8代表H C1-6烷基,苯基,苯基(C1-4烷基),COR11,COOR11,CONR9R10,其中R11是苯基,苯基(C1-4烷基)或C1-6烷基,和 R 9和R 10各自为H,C 1-6烷基,苯基或苯基(C 1-4烷基); 速激肽拮抗剂。 它们及其组合物在医学中是有用的。